R. Jumani

Cryptosporidium life cycle small molecule probing implicates translational repression and an Apetala 2 transcription factor in macrogamont differentiation

M. Love, C. McNamara, E. Stebbins, 2024, PLoS pathogens.

Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis

Juan A. Bueren-Calabuig, Andrei V. Pisliakov, David W. Gray, 2019, Proceedings of the National Academy of Sciences.

Opportunities and Challenges in Developing a Cryptosporidium Controlled Human Infection Model for Testing Antiparasitic Agents

Wilbur H. Chen, H. Tillmann, C. Ostermeier, 2021, ACS infectious diseases.

A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis

P. Schultz, A. Chatterjee, C. Huston, 2017, PLoS neglected tropical diseases.

Discovery and structure activity relationship of the first potent cryptosporidium FIKK kinase inhibitor.

W. Zuercher, Juntao Ye, M. Lautens, 2017, Bioorganic & medicinal chemistry.

Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis

J. Gut, C. Huston, J. Plattner, 2019, Nature Communications.

Targeting Prolyl-tRNA Synthetase to Accelerate Drug Discovery against Malaria, Leishmaniasis, Toxoplasmosis, Cryptosporidiosis, and Coccidiosis.

K. Harlos, F. Tacchini-Cottier, M. Matsumoto, 2017, Structure.

Methods To Identify And Develop Drugs For Cryptosporidiosis

R. S. Jumani, R. Jumani, 2018 .

Rv3881c from Mycobacterium tuberculosis Elicits PolyFunctional CD8+ T cells in PPD Positive Healthy Volunteers and Affords Significant Protection in the Guinea Pig Model

Satchidan, V. Chadha, Naveen Kumar, 2016 .

Innovations in addressing pediatric diarrhea in low resource settings.

P. Kelly, Rasa Izadnegahdar, U. Manjunatha, 2020, ACS infectious diseases.